Quanterix Appoints Former Illumina CCO Everett Cunningham as CEO with Significant Performance-Based Equity

summarizeSummary

Quanterix Corporation announced the appointment of Everett Cunningham, former Chief Commercial Officer of Illumina, as its new President and CEO, effective January 19, 2026, alongside a positive preliminary financial outlook for FY2025.

check_boxKey Events

• New CEO Appointed

  Everett Cunningham, previously Chief Commercial Officer at Illumina, was appointed President and CEO, effective January 19, 2026. He also joins the Board of Directors.

• Significant Equity Incentives

  Mr. Cunningham received 1,070,000 time-based restricted stock units (RSUs) and 813,750 performance-based RSUs, with vesting tied to stock price targets of $10, $15, and $20 per share.

• CEO Departure

  Masoud Toloue, Ph.D., resigned as President and CEO and from the Board, effective January 19, 2026, receiving severance and accelerated equity vesting.

• Positive Financial Outlook

  The company expects to exceed its revenue and cash guidance for the full fiscal year ended December 31, 2025.

auto_awesomeAnalysis

The appointment of Everett Cunningham as CEO is a highly significant development for Quanterix. Mr. Cunningham brings extensive leadership experience from major life sciences and healthcare companies like Illumina, Exact Sciences, GE Healthcare, Quest Diagnostics, and Pfizer, which is a strong positive signal for the company's strategic direction and commercial execution. His compensation package includes substantial performance-based restricted stock units tied to ambitious stock price targets of $10, $15, and $20, strongly aligning his incentives with shareholder value creation. This leadership change, coupled with the company's expectation to exceed its revenue and cash guidance for fiscal year 2025, suggests a renewed focus on growth and operational improvement.